Skip to main content
CONTEC MEDICAL SYSTEMS CO., LTD. logo

CONTEC MEDICAL SYSTEMS CO., LTD. — Investor Relations & Filings

Ticker · 300869 ISIN · CNE1000047F0 LEI · 6556007SL3V6YKCWVA55 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 789 across all filing types
Latest filing 2022-02-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300869

About CONTEC MEDICAL SYSTEMS CO., LTD.

https://www.contecmed.com.cn

CONTEC Medical Systems Co., Ltd. focuses on the research, development, manufacturing, and distribution of medical electronic instruments. The product portfolio encompasses a wide range of diagnostic and monitoring solutions, including pulse oximeters, blood pressure monitors, electrocardiographs, ultrasound equipment, and multi-parameter patient monitors. Additionally, the company provides specialized devices such as fetal monitors, sleep apnea screening systems, and biochemical analyzers. By leveraging integrated research and large-scale production facilities, the organization delivers medical technology designed for clinical, hospital, and home healthcare environments. The company emphasizes technical innovation and adheres to international quality standards to ensure the precision and reliability of its medical hardware and software solutions.

Recent filings

Filing Released Lang Actions
关于公司与秦皇岛北戴河新区管理委员会拟签订投资协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's intention to sign an investment agreement with a local government committee for a medical device industrial park project. It details the investment project, cooperation terms, rights and obligations, risk warnings, and approvals from the board and independent directors. There are no financial statements or financial performance data included. The document is a formal announcement of a capital investment agreement, not a full financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it relates to investment and financing activities of the company.
2022-02-21 Chinese
第三届董事会第十六次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the 3rd Board of Directors of 康泰医学系统（秦皇岛）股份有限公司. It details the meeting date, attendance, the approval of an investment agreement, and voting results. There is no financial data, no mention of annual or quarterly reports, no audit information, and no presentation materials. The content focuses on board decisions and meeting outcomes, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a direct disclosure of board meeting resolutions.
2022-02-21 Chinese
独立董事关于第三届董事会第十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion regarding matters discussed at the 16th meeting of the third board of directors of 康泰医学系统（秦皇岛）股份有限公司. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on approval of an investment agreement and the directors' independent judgment on the matter. There is no financial data, no report or results disclosed, and the document is a formal opinion related to board meeting matters. This fits the category of Board/Management Information (MANG), which covers announcements of changes or opinions from the board or senior management. The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2022-02-21 Chinese
关于公司新型冠状病毒抗原检测试剂盒（专业用）被列入《取得国外标准认证或注册的医疗物资企业清单》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion of a new product (COVID-19 antigen test kit) in a recognized export whitelist for overseas sales. It discusses the product certification, impact on the company, and risk factors. There is no financial data, no mention of a report being attached or published, no regulatory certification or officer attestation, and no indication of a meeting or voting results. The content is an update on product certification and market status, which fits best under general regulatory announcements. Therefore, the document is classified as a Regulatory Filing (RNS).
2022-02-17 Chinese
关于投资设立子公司完成工商注册登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of business registration for a newly established subsidiary company. It includes details about the subsidiary's registration, legal representative, capital, and business scope. There is no financial data, no mention of financial results, no regulatory certifications, or voting results. It is not a report or a presentation but a formal announcement about a corporate action related to investment and subsidiary establishment. This fits best under Capital/Financing Update (CAP) as it relates to investment and capital allocation activities.
2022-02-15 Chinese
关于投资设立子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's investment to establish a wholly-owned subsidiary. It includes details about the investment purpose, board approval, and risk disclosures. It is not a financial report, earnings release, or management discussion. The document is a formal announcement of a corporate action related to capital investment and subsidiary formation, which fits best under Capital/Financing Update (CAP). The document length is short and it contains substantive information about the investment, not just a notice or report publication announcement.
2022-02-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.